Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Frazier

Pediatrics Knoxville, TN Medical Doctor

NPI 1578657334 CMS profile 253427

2121 Highland Ave, Knoxville, TN 37916

Open in the dashboard

General payments

$4,060

208 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Frazier of Knoxville, TN is reported in the CMS Open Payments database as having received $4,060 across 208 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $599 24
2024 General $464 21
2023 General $1,071 53
2022 General $952 57
2021 General $173 6
2020 General $63 3
2019 General $739 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Frazier
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Timothy Frazier were reported at $599. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Timothy Frazier Pediatrics median Middle half National median
2019 $739 $86 $31–$183 $163
2020 $63 $49 $22–$110 $114
2021 $173 $68 $27–$158 $132
2022 $952 $77 $30–$173 $149
2023 $1,071 $88 $33–$190 $160
2024 $464 $94 $34–$206 $164
2025 $599 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $754 56 payments
  2. AstraZeneca Pharmaceuticals LP $500 27 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $470 29 payments
  4. Regeneron Healthcare Solutions, Inc. $457 19 payments
  5. Genzyme Corporation $325 13 payments
  6. Genentech USA, Inc. $256 12 payments
  7. Octapharma USA, Inc. $229 7 payments
  8. Novartis Pharmaceuticals Corporation $157 7 payments
  9. Sanofi-Aventis U.S. LLC $151 2 payments
  10. Hospira, Inc. $131 6 payments
  11. Other $632 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,909 206 payments
  2. Education $151 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $755 27 payments
  2. CUVITRU $455 29 payments
  3. NUCALA $370 30 payments
  4. DUPIXENT Inflammation And Immunology $354 15 payments
  5. FASENRA $245 12 payments
  6. Xolair $232 11 payments
  7. CUTAQUIG Immunology $229 7 payments
  8. TRELEGY ELLIPTA $169 10 payments
  9. CUTAQUIG Immunology $152 8 payments
  10. PANZYGA $152 8 payments
  11. Other $1,548 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

284

Median for Allergy/ Immunology: 449

Drug cost

$39,102

Median for Allergy/ Immunology: $169,700

Branded share of claims

42.3%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 20 $17,804
Breo Ellipta Fluticasone/Vilanterol Brand 11 $6,133
Symbicort Budesonide/Formoterol Fumarate Brand 21 $5,668
Qvar Redihaler Beclomethasone Dipropionate Brand 14 $4,552
Albuterol Sulfate Hfa Albuterol Sulfate Brand 54 $1,719
Montelukast Sodium Generic 78 $940
Ipratropium Bromide Generic 25 $866
Fluticasone Propionate Generic 33 $670
Levocetirizine Dihydrochloride Generic 16 $379
Azelastine Hcl Generic 12 $369

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$29,769

Medicare's payments for the services billed

Medicare patients

79

Average age 71

Services billed

3,043

50 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 54%
Diabetes 25%
Depression 25%
Chronic kidney disease 24%
Osteoporosis 18%
COPD 16%
Ischemic heart disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XOLAIR
  • Genentech USA, Inc. $93
  • Novartis Pharmaceuticals Corporation $29
$122 — —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $71
$71 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $39
  • GENZYME CORPORATION $26
$66 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $61
$61 — —
HYQVIA
  • Takeda Pharmaceuticals U.S.A., Inc. $30
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

208 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record